FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1–3, has demonstrated efficacy and safety in a Phase II study of patients with pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekaii-Saab, Tanios S, Valle, Juan W, Cutsem, Eric Van, Rimassa, Lorenza, Furuse, Junji, Ioka, Tatsuya, Melisi, Davide, Macarulla, Teresa, Bridgewater, John, Wasan, Harpreet, Borad, Mitesh J, Abou-Alfa, Ghassan K, Jiang, Ping, Lihou, Christine F, Zhen, Huiling, Asatiani, Ekaterine, Féliz, Luis, Vogel, Arndt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892961/
https://www.ncbi.nlm.nih.gov/pubmed/32677452
http://dx.doi.org/10.2217/fon-2020-0429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892961/
https://www.ncbi.nlm.nih.gov/pubmed/32677452
http://dx.doi.org/10.2217/fon-2020-0429

Ejemplares similares